David’s role at Proteorex involves advancing the company’s pipeline of small molecules. With over 15 years of experience in academic, biotech, and not-for-profit medicinal chemistry and drug design, he’s worked on a range of programs and platforms.
Formerly a chemistry team lead at the Structural Genomics Consortium, he was responsible for the development of chemical probes against a variety of epigenetic proteins in partnership with major pharmaceutical companies and research institutes. Prior to joining the SGC, David was a senior research chemist at MethylGene where he worked extensively on the company’s platform of small molecule HDAC inhibitors, and contributed to the development of a clinical candidate drug targeting neurodegenerative diseases. As a contributing author, his publications have appeared in top tier journals such as Nature Structural & Molecular Biology and Cancer Cell, and he also holds inventorship on a number of US patents. A trained financial analyst and project manager, David is also a certified risk manager having earned a Canadian Risk Management (CRM) designation from the Global Risk Management Institute.
After completing his BSc (First Class Honours) degree in chemistry at the University of Manitoba, he earned his PhD in organic chemistry from the University of Toronto.